Octreotide and melatonin alleviate inflammasome-induced pyroptosis through inhibition of TLR4-NF-κB-NLRP3 pathway in hepatic ischemia/reperfusion injury. 2021

Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

The Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB)/NLRP3 inflammasome signaling pathway is essential in the pathogenesis of hepatic ischemia/ reperfusion (HIR) injury. Pyroptosis is a proinflammatory programmed cell death that is related to several diseases. Thus, the purpose of this study was to examine whether pretreatment with octreotide (somatostatin analogue, OCT) at different doses or OCT at 75μg/kg combined with melatonin (N-acetyl-5-methoxytryptamine, MLT) can alleviate HIR injury via targeting NLRP3 inflammasome-induced pyroptosis in a TLR4/MyD88/NF-κB dependent manner. Rats were randomized into sham, HIR, OCT (50, 75, and 100 µg/kg), MLT, and MLT + OCT75 groups. Ischemia was induced via occlusion of the portal triad for 30 min followed by 24 h reperfusion. OCT pretreatment at doses (50 or 75 μg/kg), MLT alone, and MLT + OCT75 significantly ameliorated the biochemical with histopathological changes, oxidative stress, inflammation, apoptosis, then augmented anti-oxidant and anti-apoptotic markers through downregulation of HMGB1, TLR4, MyD88, TRAF-6, p-IκBα (S32), p-NF-κBp65 (S536), NLRP3, ASC, caspase-1(p20), and GSDMD-N expressions compared with HIR group. OCT at doses (50 or 75 µg/kg) showed for the first time a hepatoprotective effect against HIR injury via inhibiting TLR4-NLRP3-mediated pyroptosis in rats. As well, OCT75 was more effective than OCT50 or MLT alone, and its effect was not enhanced after the addition of MLT, through downregulation of TLR4/MyD88/NF-κB/NLRP3 inflammasome pathway.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000069292 Pyroptosis Type of programmed cell death associated with infection by intracellular pathogens. It is characterized by INFLAMMASOME formation; activation of CASPASE 1; and CYTOKINES mediated inflammation. Caspase-1 Dependent Cell Death,Inflammatory Apoptosis,Pyroptotic Cell Death,Apoptoses, Inflammatory,Apoptosis, Inflammatory,Caspase 1 Dependent Cell Death,Cell Death, Pyroptotic,Cell Deaths, Pyroptotic,Death, Pyroptotic Cell,Deaths, Pyroptotic Cell,Inflammatory Apoptoses,Pyroptoses,Pyroptotic Cell Deaths
D000071199 NLR Family, Pyrin Domain-Containing 3 Protein An NLR protein that contains an N-terminal PYRIN DOMAIN and ATP-binding site and 9 C-terminal LEUCINE-rich repeats; it is expressed primarily by MACROPHAGES. It is a core component of the INFLAMMASOME and directs its assembly in response to pathogen infection and damage-associated stimuli. Mutations in the NLRP3 gene are associated with FAMILIAL COLD AUTOINFLAMMATORY SYNDROME. Cold Autoinflammatory Syndrome 1 Protein,NACHT, LRR and PYD Domains-Containing Protein 3,NLRP3 Protein,NACHT, LRR and PYD Domains Containing Protein 3,NLR Family, Pyrin Domain Containing 3 Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995

Related Publications

Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
September 2017, Oncotarget,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
July 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
January 2019, Acta cirurgica brasileira,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
January 2023, Nutrients,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
April 2019, European journal of pharmacology,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
August 2023, International immunopharmacology,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
January 2023, Liver international : official journal of the International Association for the Study of the Liver,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
May 2020, Journal of molecular and cellular cardiology,
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
July 2023, Journal of molecular medicine (Berlin, Germany),
Alaa El-Din El-Sayed El-Sisi, and Samia Salim Sokar, and Abdelhadi Mohamed Shebl, and Dina Zakaria Mohamed, and Sally El-Sayed Abu-Risha
April 2022, Neuroscience letters,
Copied contents to your clipboard!